ORGS
Orgenesis Inc.0.1500
-0.0100-6.25%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
775.70KP/E (TTM)
-Basic EPS (TTM)
-24.46Dividend Yield
0%Recent Filings
10-K
FY2024 results
Orgenesis posted FY2024 revenues of $1.0M, doubling from $0.5M in 2023, driven by cell process development and hospital services that nearly doubled to $1.0M while costs plunged 69% to $1.9M, yet gross loss narrowed only to $0.9M amid persistent R&D spend. Q4 momentum flickered in OMPUL sales to Germfree, but sequential trends stayed murky with no quarterly breakdowns disclosed; impairments hammered $18M across goodwill, PP&E, and intangibles while deconsolidations shuffled $4.5M profit. Cash dwindled to $0.1M against $66M debt and $27M working capital hole. No dividends or buybacks; going concern doubt looms large. Nasdaq delisting to OTC Expert Market crimps liquidity.
8-K
Board and CFO changes
Orgenesis elected Adam Pelavin and Yaron Adler to its board on March 10, 2026, expanding it to four members; Pelavin joins audit, Adler compensation. Company appointed Doug Karriker as CFO effective same date, with $160,000 annual pay. New faces bring prior board experience and finance expertise. Leadership bolsters governance.
8-K
Issues warrant for 3.3M shares
Orgenesis issued an Alpha Warrant to its lender on January 9, 2026, exercisable for 3,289,490 common shares at a $250,000 aggregate price, tied to the first $1M drawdown under its September 2025 $1M convertible loan and $10M credit facility. The three-year warrant dilutes equity upon exercise. No further terms disclosed.
8-K
Theracell secures $1M loan
Orgenesis subsidiary Theracell inked a $1M convertible loan with Alpha Prosperity Fund on September 10, 2025, at 10% interest over 36 months, plus access to a $10M facility—$7.1M already drawn, wiping out prior $6.1M debts. The lender snags warrants for 15% equity at $250K exercise and potential board seats for three members after 30 days. Lender eyes up to 80% control via conversion, but shareholder nod required. Yet dilution looms large.
8-K
Director Ashish Nanda resigns
AURX
Nuo Therapeutics, Inc.
2.00-0.15
CLCS
Cell Source, Inc.
0.45+0.08
LCTX
Lineage Cell Therapeutics, Inc.
1.80+0.08
OGEN
Oragenics Inc.
0.83-0.01
ORGO
Organogenesis Holdings Inc.
5.17+0.34
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
ORMP
Oramed Pharmaceuticals Inc.
3.08+0.00
OSTX
OS Therapies Incorporated
1.62-0.05
RGNX
REGENXBIO Inc.
14.11+0.28
RMTG
Regenerative Medical Technology
0.04+0.00